Skip to main content
Canna~Fangled Abstracts

Maintained anxiolytic effects of cannabidiol after treatment discontinuation in healthcare workers during the COVID-19 pandemic

By October 14, 2022October 22nd, 2022No Comments

Journal List > Front Pharmacol > PMC9574068

 2022; 13: 856846.
Published online 2022 Oct 3. doi: 10.3389/fphar.2022.856846
PMCID: PMC9574068
PMID: 36263136
José Diogo S. Souza,corresponding author 1 ,* Antonio W. Zuardi, 1 , 2 Francisco S. Guimarães, 2 , 3 Flávia de Lima Osório, 1 , 2 Sonia Regina Loureiro, 1 Alline Cristina Campos, 3 Jaime E. C. Hallak, 1 , 2 Rafael G. Dos Santos, 1 , 2 Isabella Lara Machado Silveira, 1 Karina Pereira-Lima, 4 , 5 Julia Cozar Pacheco, 1 Juliana Mayumi Ushirohira, 1 Rafael Rinaldi Ferreira, 3 Karla Cristinne Mancini Costa, 3 Davi Silveira Scomparin, 3 Franciele Franco Scarante, 3 Isabela Pires-Dos-Santos, 3 Raphael Mechoulam, 6 Flávio Kapczinski, 2 , 7 , 8 Benedito A. L. Fonseca, 9 Danillo L. A. Esposito, 9 Maristela Haddad Andraus, 10 and José Alexandre S. Crippa 1 , 2
Author information Article notes Copyright and License information Disclaimer

Associated Data

Data Availability Statement

Abstract

Objective: To assess whether the effects of oral administration of 300 mg of Cannabidiol (CBD) for 28 days on mental health are maintained for a period after the medication discontinuation.

Methods: This is a 3-month follow-up observational and clinical trial study. The data were obtained from two studies performed simultaneously by the same team in the same period and region with Brazilian frontline healthcare workers during the COVID-19 pandemic. Scales to assess emotional symptoms were applied weekly, in the first month, and at weeks eight and 12.

Results: The primary outcome was that, compared to the control group, a significant reduction in General Anxiety Disorder-7 Questionnaire (GAD-7) from baseline values was observed in the CBD group on weeks two, four, and eight (Within-Subjects Contrasts, time-group interactions: F1-125 = 7.67; p = 0.006; ηp 2 = 0.06; F1-125 = 6.58; p = 0.01; ηp 2 = 0.05; F1-125 = 4.28; p = 0.04; ηp 2 = 0.03, respectively) after the end of the treatment.

Conclusions: The anxiolytic effects of CBD in frontline health care professionals during the COVID-19 pandemic were maintained up to 1 month after the treatment discontinuation, suggesting a persistent decrease in anxiety in this group in the real world. Future double-blind placebo-controlled clinical trials are needed to confirm the present findings and weigh the benefits of CBD therapy against potential undesired or adverse effects.

Keywords: Cannabidiol, CBD, Anxiety, emotional exhausion, burnout, depression, healthcare worker (HCW), follow-up

Introduction

Anxiety disorders are the most prevalent mental illnesses globally, causing high social and economic costs (). The usual pharmacological treatments for these conditions (anxiolytic and antidepressant medications) often have adverse effects and low efficacy (40%–60% of patients), with most patients failing to achieve complete remission (). Thus, it is essential to develop novel treatment approaches for anxiety disorders.

Cannabidiol (CBD) is a nonpsychotomimetic constituent of the Cannabis plant, which has potential therapeutic properties across many neuropsychiatric disorders, such as anxiety, depression, psychotic disorder, epilepsy, cognitive disorder, addiction, and other indications like chronic pain, () with a favorable safety and tolerability profile (). Several preclinical studies using different animal models have shown the potential anxiolytic properties of CBD (; ; ; ; ). These properties have been found in humans after experimentally induced anxiety in healthy volunteers (; ; ) and social phobia patients (; ). A recent small clinical trial with Japanese teenagers also showed beneficial effects of CBD in this later disorder (). However, the number of clinical studies investigating the anxiolytic effects of CBD after repeated treatment is still limited.

Moreover, considering the increase in the medicinal use of CBD in recent years, the importance of extensive real-world studies in this area has been recently highlighted 16 (). We recently showed that CBD decreased emotional exhaustion/burnout and anxiety symptoms in healthcare workers (HCWs) in a 28-days intervention () during the COVID-19 pandemic. This population is recognized as being at exceptionally high risk of developing anxiety symptoms (). In a series of prospective cases of non-frontline health workers treated with CBD during the COVID-19 pandemic, we observed that the improvement of anxiety symptoms was sustained for more than 4 weeks after the treatment discontinuation (). To verify in a controlled study if the anxiolytic effect of CBD persists for at least 4 weeks after its discontinuation, in the present paper, we conducted a 3-month follow-up of the clinical trial with frontline HCWs () and compare this group with similar demographic and professional characteristics control group from another study conducted in parallel at the same period ().

Materials and methods

Design

The data of this study were obtained from two studies with frontline HCWs involved with COVID-19 treatment performed simultaneously by the same team in the same period and region. Partial results of these studies have been published () (). One study was a clinical trial, two-arm, parallel-group, unblinded with evaluator blinded, to test the efficacy of oral CBD to prevent or reduce emotional distress in HCWs dealing with COVID-19 patients (). The other was an observational study to assess and monitor emotional distress among health workers providing care to patients with COVID-19 (). The two studies were approved by the Institutional Review Board (Process No 4.190.338 and 4.032.190).

Summary of the reference studies

The participants of the two studies were recruited between May to November 2020, during the first wave of COVID-19 in Brazil, via institutional advertising, email, and social media. The inclusion criteria were being healthcare workers (nurses, physicians, physical therapists, occupational therapists, speech therapists, psychologists, social workers, and nutritionists) of both sexes involved in the treatment of COVID-19 patients and providing their informed consent. The exclusion criteria in the clinical trial were the use of any medication with potential interactions with CBD, a history of undesirable reactions to CBD or other cannabinoids, pregnancy, and belonging to COVID-19 risk groups.

Participants of the two studies completed an online survey with scales applied weekly, in the first month, and at weeks 8–12. The primary outcome measure includes the Generalized Anxiety Disorder Questionnaire—[GAD-7] (), a 7-item self-report instrument that screens anxiety-associated symptoms rated on a three-point scale ranging from 0 (never) to 3 (almost every day). The secondary outcome measures include the Patient Health Questionnaire-9 [PHQ-9] (), a 9-item self-report instrument intended to assess depression indicators, rated from 0 (“never”) to 3 (“almost every day”); the Abbreviated Maslach Burnout Inventory-subscale emotional exhaustion [aMBI]) (), a four items that evaluate emotional depletion due to job demand on a seven-point Likert scale, ranging from 0 (“never”) to 6 (“every day”); the Posttraumatic Stress Disorder Checklist – 5 (PCL-5) (), a self-report instrument used to assess symptoms of posttraumatic stress disorder using the criteria established by the DSM-5; and a questionnaire about their demographic and professional characteristics, and personal clinical variables associated with mental health. These data were automatically stored in the RedCap platform.

In the clinical trial, in addition to the follow-up with the rankings, one group received oral CBD (99.6% purity: PurMed Global, Delray Beach, Florida, United States ) dissolved in medium-chain triglyceride oil for the first 4 weeks (150 mg twice a day). The dose of CBD was defined based on previous evidence showing that 300–400 mg/d doses promote anxiolytic effects within good safety and tolerability standards (; ; ). The treatment safety of CBD was assessed with a modified version of the UKU side effect rating scale of the Scandinavian Society of Psychopharmacology (), highlighting the most common adverse effects of CBD, the “CBD Adverse Effects Scale” (CARE Scale). In these participants, we evaluated the plasma levels of CBD and general laboratory exams in samples collected at baseline and on days 7, 14, 21, and 28.

Procedure of the present study

We compared two groups with data extracted from participants of the referred studies (; ). The healthcare workers from the clinical trial (), who received CBD during the first month of follow-up, formed one group (CBD group). The other group consisted of healthcare workers from the observational study (), who did not receive a pharmacological intervention (Control group-CG). All healthcare workers worked in institutions located in the northeast region of the state of São Paulo, Brazil (100 km around the city of Ribeirão Preto).

Participants were paired allocated into the two groups by a researcher blinded to the individual results of the rating scales. Considering that the dropouts were around twice as prominent in the study without CBD (), the participants were randomized in a 1:2 (CBD:CG) ratio concerning sex, age, and profession (Nursing or other). Assuming an effect size (Cohen’s d) of 0.1, level of significance of 0.05, and a statistical power of 0.8, we estimated that 142 participants (around 71 per group) who completed the 3 months were adequate for detecting a small effect. To obtain this number of participants at the end of 12 weeks, we selected at baseline 100 and 200 subjects in the CBD group (30% of dropouts) and Control group (65% dropouts), respectively.

Statistical analysis

Clinical and demographic data comparing CBD and Control groups at baseline, and after 12 weeks, from subjects that completed or not completed the 12-weeks observational period, were analyzed using the t-test for continuous data and the Fisher’s Exact test for nominal data. Data from the rating scales were analyzed with a repeated-measures analysis of variance (repeated-measures ANOVA) with factors time, group, and time × group interaction. The degrees of freedom of the repeated factor were corrected with Huynh-Feldt epsilon when sphericity conditions were not met. Within-subjects contrasts with a significant time × group interaction assessed the differences between groups in each measured compared to the baseline.

In the group treated with CBD during the first 4 weeks, we compared the percentage of participants that showed a reduction in clinical anxiety (cutoff score of 10 points or greater on GAD-7) in the four quartiles of the CBD plasma level. To assess whether the decrease in clinical anxiety was associated with plasma levels of CBD, we used the bipolar logistic regression (fourth quartile compared with the other quartiles). The significance level was set at p < 05.

Results

Participants

At baseline and after 12 weeks of follow-up, there was no significant difference between the CBD and Control groups concerning sex, age, occupation, psychiatric diagnosis, psychological treatment, and psychiatric medication. In addition, the same characteristics did not differ significantly between those who completed or not the 12 weeks of follow-up. Demographic and clinical characteristics are summarized in Table 1.

TABLE 1

Demographic and Clinical Characteristics of Participants.

Characteristic Baseline Completed 3 months Comparison of whether they completed 3 months
CBD Control p CBD Control p Yes No p
N = 100 N = 200 N = 71 N = 79 N = 150 N = 150
 Sex N (%)
  Female 79 (79) 153 (76.5) 0.626 56 (78.9) 63 (79.7) 0,895 119 (79.3) 113 (75.3) 0.408
  Male 21(21) 47 (23.5) 15 (21.1) 16 (20.3) 31 (20.7) 37 (24.7)
 Age (years) Mean (SD)
34.45 (7.30) 34.75 (9.56) 0.783 34.51 (7.36) 35.6 (10.16) 0.458 35.08 (8.93) 34.22 (8.79) 0.401
 Occupation – No. (%)
  Nurse 44 (44) 105 (52.5) 0.165 30 (42.3) 36 (45.6) 0,136 73 (48.7) 76 (50.7) 0.729
  Other 56 (56) 95 (47.5) 41 (57.7) 43 (54.4) 77 (51.3) 74(49.3)
 Psychiatric diagnosis No. (%)
  Yes 22(22) 52 (26) 0.397 16 (22.5) 26 (32.9) 0,158 42 (28) 32 (21.1) 0.16
  No 78 (78) 148 (74) 55(77.5) 53 (67.1) 108 (72) 120 (78.9)
 Psychological treatment – No. (%)
  Yes 43 (43) 86 (43) 1.0 27 (38) 39 (49.4) 0,162 66 (44) 63 (42) 0.726
  No 57 (57) 114 (57) 44 (62) 40 (50.6) 84 (56) 87 (58)
 Psychiatric medication No. (%)
  Yes 20 (20) 44 (22) 0.630 16 (22.5) 26 (32.9)) 0,158 36 (24) 28 (18.67) 0.236
  No 80(80) 156 (78) 55 (75.5) 53 (67.1) 114 (76) 122 (81.33)

Primary outcome

The ANOVA repeated measures of GAD-7 scores showed a significant effect of time (F3.28-410.18 = 8.18; p < 0.001; ηp 2 = 0.06), group (F1-125 = 4.69; p = 0.03; ηp 2 = 0.04), and time-group interaction (F3.28-410.18 = 3.51; p = 0.01; ηp 2 = 0.03). Compared to Control group, a significant reduction in delta score concerning baseline values was observed in the CBD group on weeks two, four, and eight (Within-Subjects Contrasts, time-group interactions: F1-125 = 7.67; p = 0.006; ηp 2 = 0.06; F1-125 = 6.58; p = 0.01; ηp 2 = 0.05; F1-125 = 4.28; p = 0.04; ηp 2 = 0.03, respectively). Figure 1A showed the delta score, concerning baseline values in weeks 2,4,8, and 12. The repeated measures ANOVA of the GAD-7 scores showed a significant effect of time only for the CBD group (F3.46-235.05 = 10.56; p < 0.001; ηp 2 = 0.13). The differences between the basal and the other time points are shown in Figure 1A.

An external file that holds a picture, illustration, etc. Object name is fphar-13-856846-g001.jpg

Results for Anxiety (A), depression (B), emotional exhaustion (C), and posttraumatic stress (D).

In the group treated with CBD during the first 4 weeks, the percentage of participants that showed a reduction in clinical anxiety in the four quartiles of the CBD plasma level was shown in Figure 2. CBD plasma levels were significantly associated with the reduction in clinical anxiety (Odd ratio = 8.854; Confidence interval = 1.146-68.386; p = 0.037).

An external file that holds a picture, illustration, etc. Object name is fphar-13-856846-g002.jpg

Association between CBD plasma levels and anxiety symptoms.

Secondary outcome

The delta score concerning baseline values of the scales PHQ-9, aMBI, and PCL-5 was shown in Figure 1 as well.

There were significant effects of time (F3.31-443.49 = 5.37; p < 0.001; ηp 2 = 0.04), group (F1-134 = 4.85; p = 0.03; ηp 2 = 0.04), and tendency to significant effect of time × group interaction (F3.31-443.49 = 2.09; p = 0.08; ηp 2 = 0.02), on PHQ-9 scores. The Within-Subjects Contrasts showed a significant effect of time × group interaction on weeks two (F1-134 = 4.02; p = 0.04; ηp 2 = 0.03), four (F1-134 = 4.23; p = 0.04; ηp 2 = 0.03), and eight (F1-134 = 5.32; p = 0.02; ηp 2 = 0.04), with a lower value in CBD group (Figure 1B). The repeated measures ANOVA of the PHQ-9 scores showed a significant effect of time only for the CBD group [F3.36-228.23 = 5.62; p = 0.001; ηp 2 = 0.08]. The differences between the basal and the other time points are shown in Figure 1B.

Concerning aMBI scores, there were significant effects of group (F1-133 = 6.04; p = 0.02; ηp 2 = 0.04), and time × group interaction (F3.57-474.03 = 3.19; p = 0.02; ηp 2 = 0.02), but no significant effect of time (F3.57-474.03 = 3.19; p = 0.02; ηp 2 = 0.02). The Within-Subjects Contrasts showed a significant effect of time × group interaction on weeks four (F1-133 = 8.73; p = 0.004; ηp 2 = 0.06), and eight (F1-133 = 6.66; p = 0.01; ηp 2 = 0.05), with a lower value in CBD group. (Figure 1C). The repeated measures ANOVA of the aMBI scores showed a significant effect of time only for the CBD group (F3.18-216.23 = 3.57; p = 0.007; ηp 2 = 0.05). The differences between the basal and the other time points can be seen in Figure 1C.

The repeated measures ANOVA of the PCL scores did not show a significant effect of time (F3.19-414.59 = 2.08; p = 0.1; ηp 2 = 0.02), group (F1-130 = 0.02; p = 0.89; ηp 2<0.001), and time-group interactions (F3.19-414.59 = 0.85; p = 0.47; ηp 2 = 0.006). The repeated measures ANOVA of the PCL scores showed a significant effect of times only for the CBD group (F3.41-235.10 = 2.61; p = 0.036; ηp 2 = 0.04). The differences between the basal and the other time points are shown in Figure 1D.

Safety of cannabidiol treatment

The serious adverse events observed during the 4 weeks of CBD treatment were increased hepatic enzymes greater than three times the upper limit (4%), none with total serum bilirubin levels greater than two-fold, and reports of skin erythema diagnosed as pharmacodermia (4%) (). All cases fully recovered after CBD discontinuation. The most common adverse effects were somnolence (19%), diarrhea (15%), increased appetite (11%), and fatigue (10%).

Discussion

This observational and clinical trial study combination follow-up showed that CBD’s beneficial effects on mental health were maintained after 1 month of its discontinuation in frontline HCWs during the COVID-19 pandemic. Compared to the control group, these effects included a reduction in anxiety, depressive, and emotional exhaustion/burnout symptoms measured by the GAD-7, PHQ-9, and aMBI scores, respectively. Furthermore, there was a statistically significant association between the higher CBD plasma level and the lower number of participants with scores indicative of anxiety (GAD-7 score >9 points. Overall, existing preclinical and clinical evidence support a potential role for CBD as a novel treatment for anxiety disorders (). The clinical evidence to date is mostly based on acute single-dose studies. Therefore, the present research contributes by showing not only the beneficial effects of daily CBD administration for 28 days but also that these effects are maintained over a similar period. Since the half-life of CBD after chronic oral administration is between two and 5 days (), the maintenance of the anxiety and emotional exhaustion attenuation could not be attributed to the plasma level of the drug. Instead, one possible explanation is that a period of less anxiety at work induced by CBD would transiently change their aversive memory concerning the work by their effects of enhancing the extinction () or interfering with the reconsolidation of traumatic memories (). However, these effects did not occur in depression and post-traumatic stress disorder. The discontinuation of CBD after 4 weeks did not induce withdrawal signs.

Cannabis products are widely employed worldwide, and their use has been illegalized in several countries (). After legalizing medicinal and recreational cannabis in some countries, its use highly increased (; ; ). CBD has gained special attention for its therapeutic potency for several physical and mental health conditions (). Anxiety is regularly one of the most frequent conditions for which patients use cannabis (), particularly pure CBD products () There are other anxiolytic drugs; however, these can have some adverse effects that are even more harmful to healthcare professionals on the front lines of caring for COVID-19 patients. Among these, we can mention sedation, cognitive dysfunction, decreased performance of benzodiazepines () and latency to onset of anxiolytic effects with a possible increase in anxiety, at the beginning of treatment, with antidepressants (). Therefore, considering the increase in the medicinal use of CBD in recent years, extensive real-world studies on this area are urgently needed.

Treatment with cannabidiol was associated with few reported cases of serious AEs, which resolved after drug discontinuation. Still, their presence highlights the need for close clinical monitoring (especially liver function testing) of patients receiving CBD therapy (). To our knowledge, this is the first study to assess the effects of CBD even after the medication discontinuation. Thus, the present work results could significantly impact the medicinal cannabinoids used worldwide. However, more clinical trials are needed to assess the long-term effects of Cannabidiol.

Limitations

The main limitation is that the samples compared, although with similar demographic and professional characteristics, are from different studies. An ideal protocol would include a placebo-controlled treatment to discard a putative placebo effect in the CBD group. However, the main objective of this study was to evaluate the duration of the effects observed after the treatment discontinuation, and in the 2 months after CBD treatment, the two groups had the same protocol, only the monitoring with self-evaluated scales. In addition, the much lower dropout rate in the control (65%) compared to the CBD-treated group (30%) could reflect a more significant beneficial effect observed in this group. Since the survey was online, no urine tests were made to rule out substance use.

Conclusion

This observational and clinical trial study combination follow-up showed that the beneficial effects on anxiety, emotional exhaustion/burnout, and depressive symptoms observed among frontline health care professionals working with patients with COVID-19 after 28 days of daily CBD administration were maintained for up to a month after the treatment discontinuation. This study meets the recently highlighted need for extensive real-world studies on CBD’s potential medicinal use. Future double-blind placebo-controlled clinical trials are needed to assess the CBD long-term effects and confirm the present findings.

Data availability statement

The original contributions presented in the study are included in the article, further inquiries can be directed to the corresponding author.

Ethics Statement

The studies involving human participants were reviewed and approved by the Institutional Review Board (Process No 4.190.338 and 4.032.190). The participants provided their written informed consent to participate in this study.

Author contributions

JS, AZ, JP, FG, FO, and SL: Conception and design or analysis and interpretation of data and final approval of the present study. All other authors are related to the two substudies that provided the samples for this present study: Conception and design or analysis and interpretation of data. All authors contributed to the article and approved the submitted version.

Funding

This work was supported by grants from The São Paulo Research Foundation (2014/50891-1; 2020/12110-9); Grant 2008/09009-2 from the National Institute of Translational Science and Technology in Medicine; National Council for Scientific and Technological Development (401058/2020-4; 465458/2014-9); Productivity Research Fellows: No. 302601/2019-8 (FO); 307945/2018-9 (SL); in-kind donations of cannabidiol from PurMed Global; and donated services (dosing plasma levels of cannabidiol) from Laboratório Chromatox. The funding organizations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Conflict of interest

AZ reported receiving grants from the National Institute of Translational Science and Technology in Medicine and personal fees from the National Council for Scientific and Technological Development during the conduct of the study, being a co-owner of a patent for fluorinated cannabidiol compounds (licensed to Phytecs), and having a patent pending for a cannabinoid-containing oral pharmaceutical composition outside the submitted work. FG reported receiving grants from Prati-Donaduzzi, being a co-owner of a patent for fluorinated cannabidiol compounds (licensed to Phytecs), and having a patent pending for a cannabinoid-containing oral pharmaceutical composition outside the submitted work. AC reported having a patent pending for a cannabinoid-containing oral pharmaceutical composition outside the submitted work. JH reported receiving grants from Prati-Donaduzzi, travel support and personal fees from BioSynthesis Pharma Group, being a co-owner of a patent for fluorinated cannabidiol compounds (licensed to Phytecs), and having a patent pending for a cannabinoid-containing oral pharmaceutical composition outside the submitted work. RD Santos reported receiving grants from the National Council for Scientific and Technological Development during the conduct of the study. RM reported being a co-owner of a patent for fluorinated cannabidiol compounds (licensed to Phytecs) outside the submitted work. FK reported receiving grants from the Canada Foundation for Innovation, the National Council for Scientific and Technological Development, Mitacs, and the Stanley Medical Research Institute; personal fees from Aché Laboratorios Farmaceuticos, Daiichi Sankyo, and Janssen-Cilag; and being a co-owner of a patent for fluorinated cannabidiol compounds (licensed to Phytecs) outside the submitted work. MA reported receiving technical support from Salomao Zoppi Serviços Médicos e Participações during the conduct of the study and personal fees from Laboratório Chromatox outside the submitted work. JC reported receiving grants from the São Paulo Research Foundation and the National Institute of Translational Science and Technology in Medicine and personal fees from the National Council for Scientific and Technological Development and Salomão e Zoppi Serviços Médicos e Participações during the conduct of the study and receiving travel support and personal fees from BioSynthesis Pharma Group; serving as a member of the international advisory board of the Australian Centre for Cannabinoid Clinical and Research Excellence, National Health and Medical Research Council; being a co-owner of a patent for fluorinated cannabidiol compounds (licensed to Phytecs); and having a patent pending for a cannabinoid-containing oral pharmaceutical composition outside the submitted work. No other disclosures were reported.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

  • Bandelow B., Sher L., Bunevicius R., Hollander E., Kasper S., Zohar J., et al. (2012). Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. Int. J. Psychiatry Clin. Pract. 16, 77–84. 10.3109/13651501.2012.667114 [PubMed] [CrossRef] []
  • Bergamaschi M. M., Queiroz R. H., Chagas M. H. N., de Oliveira D. C. G., De Martinis B. S., Kapczinski F., et al. (2011). Cannabidiol reduces the anxiety induced by simulated public speaking in treatment naïve social phobia patients. Neuropsychopharmacology 36 (6), 1219–1226. 10.1038/npp.2011.6 [PMC free article] [PubMed] [CrossRef] []
  • Bergamaschi M. M., Queiroz R. H., Zuardi A. W., Crippa J. A. (2011). Safety and side effects of cannabidiol, a Cannabis sativa constituent. Curr. Drug Saf. 6, 237–249. 10.2174/157488611798280924 [PubMed] [CrossRef] []
  • Bolsoni L. M., Crippa J. A. S., Hallak J. E. C., Guimarães F. S., Zuardi A. W. (2022). Effects of cannabidiol on symptoms induced by the recall of traumatic events in patients with posttraumatic stress disorder. Psychopharmacology 239, 1499–1507. 10.1007/s00213-021-06043-y [PubMed] [CrossRef] []
  • Bonomo Y., Souza J. D. S., Jackson A., Crippa J. A. S., Solowij N. (2018). Clinical issues in cannabis use. Br. J. Clin. Pharmacol. 84, 2495–2498. 10.1111/bcp.13703 [PMC free article] [PubMed] [CrossRef] []
  • Campos A. C., Ferreira F. R., Guimarães F. S. (2012). Cannabidiol blocks long lasting behavioral consequences of predator threat stress: Possible involvement of 5HT1A receptors. J. Psychiatr. Res. 46, 1501–1510. 10.1016/j.jpsychires.2012.08.012 [PubMed] [CrossRef] []
  • Campos A. C., Guimaraes F. S. (2009). Evidence for a potential role for TRPV1 receptors in the dorsolateral periaqueductal gray in the attenuation of the anxiolytic effects of cannabinoids. Prog. Neuropsychopharmacol. Biol. Psychiatry 33 (8), 1517–1521. 10.1016/j.pnpbp.2009.08.017 [PubMed] [CrossRef] []
  • Carlotto M. S., Camara S. G. (2007). Artigo parcialmente retratado: Propriedades psicométricas do Maslach burnout inventory em uma amostra multifuncional. Estud. Psicol. 24 (3), 325–332. 10.1590/S0103-166X2007000300004 [CrossRef] []
  • Crippa J. A., Derenusson G. N., Ferrari T. B., Wichert-Ana L., Duran F. L., Martin-Santos R., et al. (2011). Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: A preliminary report. J. Psychopharmacol. 25, 121–130. 10.1177/0269881110379283 [PubMed] [CrossRef] []
  • Crippa J. A., Guimarães F. S., Campos A. C., Zuardi A. W. (2018). Translational investigation of the therapeutic potential of cannabidiol (CBD): Toward a new age. Front. Immunol. 21, 2009. 10.3389/fimmu.2018.02009 [PMC free article] [PubMed] [CrossRef] []
  • Crippa J. A. S., Zuardi A. W., Guimarães F. S., Campos A. C., de Lima Osório F., Loureiro S. R., et al. (2021). Efficacy and safety of cannabidiol plus standard care vs standard care alone for the treatment of emotional exhaustion and burnout among frontline health care workers during the COVID-19 pandemic: A randomized clinical trial. JAMA Netw. Open 4, e2120603. 10.1001/jamanetworkopen.2021.20603 [PMC free article] [PubMed] [CrossRef] []
  • Das R. K., Kamboj S. K., Ramadas M., Yogan K., Gupta V., Redman E., et al. (2013). Cannabidiol enhances consolidation of explicit fear extinction in humans. Psychopharmacology 226 (4), 781–792. 10.1007/s00213-012-2955-y [PubMed] [CrossRef] []
  • de Lima Osório F., Mendes A. V., Crippa J. A., Loureiro S. R. (2009). Study of the discriminative validity of the PHQ-9 and PHQ-2 in a sample of Brazilian women in the context of primary health care. Perspect. Psychiatric Care 45, 216–227. 10.1111/j.1744-6163.2009.00224.x [PubMed] [CrossRef] []
  • Guimarães F. S., Chiaretti T. M., Graeff F. G., Zuardi A. W. (1990). Antianxiety effect of cannabidiol in the elevated plus-maze. Psychopharmacology 100, 558–559. 10.1007/BF02244012 [PubMed] [CrossRef] []
  • Hasin D. S., Sarvet A. L., Cerdá M., Keyes K. M., Stohl M., Galea S., et al. (2017). US adult illicit cannabis use, cannabis use disorder, and medical marijuana laws: 1991-1992 to 2012-2013. JAMA Psychiatry 74, 579–588. 10.1001/jamapsychiatry.2017.0724 [PMC free article] [PubMed] [CrossRef] []
  • Lader M. (2014). Benzodiazepine harm: How can it be reduced? Br. J. Clin. Pharmacol. 77 (2), 295–301. 10.1111/j.1365-2125.2012.04418.x [PMC free article] [PubMed] [CrossRef] []
  • Leas E. C., Hendrickson E. M., Nobles A. L., Todd R., Smith D. M., Dredze M., et al. (2020). Self-reported cannabidiol (CBD) use for conditions with proven therapies. JAMA Netw. Open 3, e2020977. 10.1001/jamanetworkopen.2020.20977 [PMC free article] [PubMed] [CrossRef] []
  • Linares I., Zuardi A. W., Pereira L. C., Hallak J. E. C., Queiroz R. H. C., Guimarães F. S., et al. (2018). Cannabidiol presents an inverted U-shaped dose-response curve in the simulated public speaking test. Eur. Neuropsychopharmacol. 26, S617. 10.1016/S0924-977X(16)31702-3 [PMC free article] [PubMed] [CrossRef] []
  • Lingjaerde O. (1987). The UKU side effect rating scale: A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr. Scand. Suppl. 334, 1–100. 10.1111/j.1600-0447.1987.tb10566.x [PubMed] [CrossRef] []
  • Martins S. S., Mauro C. M., Santaella-Tenorio J., Kim J. H., Cerda M., Keyes K. M., et al. (2016). State-level medical marijuana laws, marijuana use and perceived availability of marijuana among the general U.S. population. Drug Alcohol Depend. 169, 26–32. 10.1016/j.drugalcdep.2016.10.004 [PMC free article] [PubMed] [CrossRef] []
  • Masataka N. (2019). Anxiolytic effects of repeated cannabidiol treatment in teenagers with social anxiety disorders. Front. Psychol. 10, 2466. 10.3389/fpsyg.2019.02466 [PMC free article] [PubMed] [CrossRef] []
  • Millar S. A., Stone N. L., Yates A. S., O’Sullivan S. E. (2018). A systematic review on the Pharmacokinetics of cannabidiol in Humans. Front. Pharmacol. 9, 1365. 10.3389/fphar.2018.01365 [PMC free article] [PubMed] [CrossRef] []
  • Moreira F. A., Aguiar D. C., Guimarães F. S. (2006). Anxiolytic-like effect of cannabidiol in the rat Vogel conflict test. Prog. Neuropsychopharmacol. Biol. Psychiatry 30, 1466–1471. 10.1016/j.pnpbp.2006.06.004 [PubMed] [CrossRef] []
  • Moreno A. L., DeSousa D. A., Souza A. M. F. L., Manfro G. G., Salum G. A., Koller S. H., et al. (2016). Factor structure, reliability, and item parameters of the Brazilian-Portuguese version of the GAD-7 questionnaire. Temas Psicol. 24, 367–376. 10.9788/tp2016.1-25 [CrossRef] []
  • Moreno A. R., Moreno D. H., Soares M. B. M. (1999). Psicofarmacologia de antidepressivos. Braz. J. Psychiatry. 21 (1), 24–40. 10.1590/S1516-44461999000500006 [CrossRef] []
  • Osório F. L., da Silva T. D. A., Dos Santos R. G., Chagas M. H. N., Chagas N. M. S., Sanches R. F., et al. (2017). Posttraumatic stress disorder checklist for DSM-5 (PCL-5): Transcultural adaptation of the Brazilian version. Archives Clin. Psychiatry 44, 10–19. 10.1590/0101-60830000000107 [CrossRef] []
  • Osório F. L., Silveira I. L. M., Pereira-Lima K., Crippa J. A. de S., Hallak J. E. C., Zuardi A. W., et al. (2021). Risk and protective factors for the mental health of Brazilian healthcare workers in the frontline of COVID-19 pandemic. Front. Psychiatry 12, 662742. 10.3389/fpsyt.2021.662742 [PMC free article] [PubMed] [CrossRef] []
  • Pacheco J. C., Souza J. D., Hallak J. E. C., Osório F. L., Campos A., Guimarães F. S., et al. (2021). Cannabidiol as a treatment for mental health OutcomesAmong health care workers during the coronavirus disease pandemic. J. Clin. Psychopharmacol. 41 (3), 327–329. 10.1097/JCP.0000000000001405 [PubMed] [CrossRef] []
  • Sahebi A., Nejati-Zarnaqi B., Moayedi S., Yousefi K., Torres M., Golitaleb M. (2021). The prevalence of anxiety and depression among healthcare workers during the COVID-19 pandemic: An umbrella review of meta-analyses. Prog. Neuropsychopharmacol. Biol. Psychiatry 107, 110247. 10.1016/j.pnpbp.2021.110247 [PMC free article] [PubMed] [CrossRef] []
  • Schlag A. K., O’Sullivan S. E., Zafar R. R., Nutt D. J. (2021). Current controversies in medical cannabis: Recent developments in human clinical applications and potential therapeutics. Neuropharmacology 191, 108586. 10.1016/j.neuropharm.2021.108586 [PubMed] [CrossRef] []
  • Sholler D. J., Schoene L., Spindle T. R. (2020). Therapeutic efficacy of cannabidiol (CBD): A review of the evidence from clinical trials and human laboratory studies. Curr. Addict. Rep. 7, 405–412. 10.1007/s40429-020-00326-8 [PMC free article] [PubMed] [CrossRef] []
  • Soares V. P., Campos A. C., Bortoli V. C., Zangrossi H., Guimarães F. S. (2010). Intra-dorsal periaqueductal gray administration of cannabidiol blocks panic-like response by activating 5-HT1A receptors. Behav. Brain Res. 213 (2), 225–229. 10.1016/j.bbr.2010.05.004 [PubMed] [CrossRef] []
  • Souza J. D. S., Fassoni-Ribeiro M., Batista R. M., Ushirohira J. M., Zuardi A. W., Guimarães F. S., et al. (2022). Case report: Cannabidiol-induced skin rash: A case series and key recommendations. Front. Pharmacol. 13, 881617. 10.3389/fphar.2022.881617 [PMC free article] [PubMed] [CrossRef] []
  • Stein D. J., Scott K. M., de Jonge P., Kessler R. C. (2017). Epidemiology of anxiety disorders: From surveys to nosology and back. Dialogues Clin. Neurosci. 19, 127–136. 10.31887/DCNS.2017.19.2/dstein [PMC free article] [PubMed] [CrossRef] []
  • Wen H., Hockenberry J. M., Cummings J. R. (2015). The effect of medical marijuana laws on adolescent and adult use of marijuana, alcohol, and other substances. J. Health Econ. 42, 64–80. 10.1016/j.jhealeco.2015.03.007 [PubMed] [CrossRef] []
  • Zuardi A. W., Cosme R. A., Graeff F. G., Guimarães F. S. (1993). Effects of ipsapirone and cannabidiol on human experimental anxiety. J. Psychopharmacol. 7 (1), 82–88. 10.1177/026988119300700112 [PubMed] [CrossRef] []
  • Zuardi A. W., Rodrigues N. P., Silva A. L., Bernardo S. A., Hallak J. E. C., Guimarãe F. S., et al. (2017). Inverted U-shaped dose-response curve of the anxiolytic effect of cannabidiol during public speaking in real life. Front. Pharmacol. 8, 259. 10.3389/fphar.2017.00259 [PMC free article] [PubMed] [CrossRef] []
Articles from Frontiers in Pharmacology are provided here courtesy of Frontiers Media SA

Leave a Reply